|
Patent landscape, scope, and claims: |
United States Patent 9,827,242 Scope, Claims, and Lurasidone Attention-Improvement Landscape
United States Patent 9,827,242 claims a method-of-use centered on lurasidone (or acid-addition salts) as the sole active ingredient for improving attention function in schizophrenia and/or bipolar disorder. The claim set is narrow in drug identity (“sole active ingredient”) and breadth in clinical outcome (“improving attention function”), with dependent claims narrowing to tablet dosage ranges (20 mg to 160 mg/day) and specific attention sub-domains (continuous concentration, rapid-reaction, reduced activity). This structure points to a relatively compact enforcement footprint against method substitutions (other drugs, combination regimens, non-tablet presentations, or different active ingredients), while still creating licensing leverage for label-adjacent “attention” indications and trial design.
What does US Patent 9,827,242 claim for lurasidone attention improvement?
What is the core independent claim scope (Claim 1)?
Claim 1 is the anchor and reads as follows in substance:
- A method to improve attention function in schizophrenia and/or bipolar disorder.
- Administer a pharmaceutical composition to a mammal in need thereof.
- The composition contains, as the sole active ingredient, a therapeutically effective amount of:
- lurasidone, or
- a pharmaceutically acceptable acid addition salt of lurasidone.
Key legal and claim-construction levers
- Drug limitation is absolute: “sole active ingredient” bars compositions with any additional active agents (including adjunct cognitive enhancers, stimulants, antidepressants with active antidepressant ingredients, or other antipsychotics/mood stabilizers).
- Outcome limitation is functional: “improving attention function” is not limited to a particular test battery in the claim text provided. That supports a broader factual pathway for infringement: any clinically recognized attention improvement tied to the claimed administration could be argued to satisfy the functional limitation.
- Indication limitation is bipolar and/or schizophrenia: no other psychiatric populations are claimed in the provided text.
What do dependent claims add (Claims 2–6)?
- Claim 2 narrows to:
- dosage form: tablet
- active: lurasidone hydrochloride
- dosing: 20 mg to 160 mg/day
- Claims 3–4 specify:
- attention improvement in bipolar disorder (Claim 3) or
- attention improvement in schizophrenia (Claim 4)
- Claim 5 provides attention subdomains:
- improving impairment in continuous concentration
- improving diminished rapid-reaction
- improving reduced activity
- Claim 6 captures:
- improving attention function with the specific subdomain “improving reduced activity,”
- with lurasidone (or acid-addition salt) as sole active ingredient (again consistent with Claim 1’s drug limitation).
How broad is “improving attention function” in the claims of US 9,827,242?
Is “attention function” tied to objective assays or clinical instruments?
The claim text provided does not specify a particular biomarker, cognitive test name, or scoring threshold. That means infringement analysis will likely focus on:
- the clinical endpoint used in the administration context (trial or practice setting), and
- whether the reported outcome is characterized as “attention function” or a recognized attention component.
Claim 5 supplies subdomains (“continuous concentration,” “rapid-reaction,” “reduced activity”), which narrows interpretive space in those scenarios. Still, absent a test name, the claim language remains compatible with multiple cognitive batteries often used in psychiatric trials.
What attention impairment theories are covered?
From Claim 5 and Claim 6, the patent expressly covers three attention-related impairment vectors:
- Continuous concentration impairment
- Diminished rapid-reaction
- Reduced activity
Claim 6 further isolates “improving reduced activity” as an attention function improvement scenario.
Does the “sole active ingredient” limitation materially narrow infringement risk for lurasidone combinations?
Direct impact on combination regimens
Because the claims require that the pharmaceutical composition has, as the sole active ingredient, lurasidone or a pharmaceutically acceptable acid-addition salt, infringement is strongly disfavored where the composition includes any other active ingredient.
Practical implications:
- Adjunct therapy using co-administered drugs typically increases non-infringement defenses because the composition may not satisfy “sole active ingredient.”
- Fixed-dose combinations (if any) would be high-risk only if they are not “additional active ingredients,” which is unusual.
- In practice (not just in trials), clinicians often co-prescribe mood stabilizers, antipsychotics, antidepressants, or stimulants. Those practice patterns are potential design-around points for parties aiming to avoid “sole active ingredient” in the pharmaceutical composition itself.
What about co-administration with other drugs?
The language provided says “administering a pharmaceutical composition comprising, as the sole active ingredient” lurasidone. That focuses on the composition, not necessarily on the overall regimen across separate products. In infringement scenarios, plaintiffs may still argue “composition” includes what is administered together, but claim construction often treats each dosage form separately. This is a decisive risk variable in litigation, licensing, and design-around planning.
What patents protect lurasidone methods for improving attention in schizophrenia or bipolar disorder in the US?
How the claim structure interacts with typical lurasidone IP families
US lurasidone IP historically includes:
- composition and formulation patents (including polymorphs, salts, and solid oral forms),
- method-of-treatment patents for psychiatric conditions,
- possibly dosage and regimen-specific patents,
- and later-life claims around specific patient subpopulations and clinical endpoints.
Patent 9,827,242 is a method-of-use centered on an attention endpoint, with a relatively clean “sole active ingredient” constraint.
Method-of-use claim clustering likely used by challengers
In freedom-to-operate reviews, attention-improvement methods usually face challenges by asserting overlap with:
- earlier method patents where “cognition” or “cognitive impairment” was claimed broadly,
- earlier psychiatric indication patents that used cognitive/attention endpoints as secondary outcomes,
- or obviousness arguments based on known lurasidone efficacy in related domains.
This patent’s special vulnerability is the functional endpoint without test specificity. Defendants can target the novelty step by arguing that attention improvement is an inherent or obvious consequence of treating schizophrenia/bipolar with an antipsychotic with known effects on cognition/processing speed.
What is the claim scope for tablets and lurasidone hydrochloride dosage (Claim 2)?
What does Claim 2 cover precisely?
Claim 2 narrows to:
- “pharmaceutical composition is a tablet”
- lurasidone or salt is “lurasidone hydrochloride”
- orally administered dosage: 20 mg to 160 mg per day
This claim creates a stronger, more objective infringement hook in at least two ways:
- It ties infringement to a specific dosage form (tablet).
- It ties it to a specific salt identity (hydrochloride).
- It ties it to a dosage band.
What does Claim 2 not cover (based on provided text)?
- It does not claim extended-release, oral suspension, or other delivery systems.
- It does not claim other salts besides hydrochloride (although Claim 1 covers acid-addition salts generally).
Design-around strategy typically targets delivery form and/or salt identity for cases where only Claim 2 is asserted.
When does US 9,827,242 lose exclusivity, and how do exclusivity vs patent expiry interact?
No expiration or term data is provided in the prompt. Without the filing date, priority date, and whether the patent has any terminal disclaimers, PTA, or adjustment, the exclusivity timeline cannot be computed accurately.
What generic entry risks exist for lurasidone attention-improvement methods tied to US 9,827,242?
Is this a composition patent or a method patent?
This is a method-of-use patent. That matters for generic entry:
- Generic companies typically can market a therapeutically equivalent lurasidone product (assuming formulation/bioequivalence issues are cleared) without being stopped by method patents unless their labeling or their manufacturing/marketing steps induce infringement.
- The key legal risk is Paragraph IV-style exposure only if the generic’s ANDA is tied to an Orange Book-listed patent covering the claimed method and the carve-out is not available.
Where infringement risk usually concentrates
- If a label or label supplement explicitly describes attention improvement in schizophrenia/bipolar as an indication or claim of clinical benefit, that increases infringement risk against the “use” method.
- Litigation often focuses on induced infringement theories (marketing, labeling, and instructions to practice the patented method).
Without the Orange Book listing context and the specific FDA labeling language tied to the patent, infringement risk cannot be mapped to actual ANDA entry scenarios in the US.
What does the claim set imply about litigation strategy for parties challenging or licensing US 9,827,242?
If asserting the patent
Plaintiffs will typically focus on:
- demonstrating that the administered therapy uses lurasidone (or hydrochloride, for Claim 2) as the sole active ingredient,
- pinning “attention function” improvements to the claimed subdomains (continuous concentration, rapid-reaction, reduced activity),
- aligning dosing with the claim band for tablet/hydrochloride scenarios.
If challenging the patent
Common attack angles consistent with the claim language provided:
- arguing “attention function” lacks clear boundaries and is anticipated/obvious by prior lurasidone schizophrenia/bipolar cognitive outcomes,
- challenging novelty of subdomain endpoints (continuous concentration, rapid-reaction, reduced activity) as being disclosed or inherently achievable,
- contesting “sole active ingredient” under composition-level interpretations,
- attacking dependent-claim limitations (tablet identity, hydrochloride, dosage band) where clinical use differs.
How does US 9,827,242 compare with broader lurasidone method patents for schizophrenia and bipolar disorder?
Distinctive aspect: attention as the treated function
Many lurasidone method-of-treatment patents focus on symptom clusters such as schizophrenia positive symptoms, negative symptoms, depressive episodes in bipolar disorder, or psychosis. Patent 9,827,242 narrows to “attention function” and further specifies attention impairment vectors.
Distinctive aspect: sole active ingredient
Other method patents often do not include the strict “sole active ingredient” constraint, meaning they can be infringed even in combination regimens depending on jurisdiction and claim construction. Here, “sole active ingredient” is a materially limiting feature.
Key patent landscape takeaways specific to the 9,827,242 claim architecture
Most enforceable claim hooks
- Claim 1: lurasidone (or acid-addition salt) as sole active ingredient + attention improvement in schizophrenia/bipolar
- Claim 2: tablet + lurasidone hydrochloride + 20–160 mg/day + attention improvement
- Claims 5–6: attention subdomain framing (“continuous concentration,” “rapid-reaction,” “reduced activity”)
Most likely design-around levers
- Avoiding compositions with other active ingredients (for strict “sole active ingredient” compliance)
- Using non-tablet dosage forms, if claim 2 is targeted
- Avoiding lurasidone hydrochloride specifically, if claim 2 is targeted
- Selecting dosing regimens outside 20–160 mg/day, if claim 2 is asserted
Key Takeaways
- US 9,827,242 is a method-of-use patent focused on lurasidone or its acid-addition salts as the sole active ingredient for improving attention function in schizophrenia and/or bipolar disorder.
- The independent claim (Claim 1) is broad on endpoint framing (“improving attention function”) but narrow on drug composition (“sole active ingredient”).
- Dependent Claim 2 adds concrete infringement conditions: tablet dosage form, lurasidone hydrochloride, and oral dosing of 20 mg to 160 mg/day.
- Claims 5 and 6 tighten the clinical endpoint into attention subdomains, including continuous concentration, diminished rapid-reaction, and reduced activity.
- Exclusivity timelines, Orange Book status, and generic entry risk cannot be determined from the provided information because the prompt omits filing/priority dates, FDA listing context, and label linkage.
FAQs
-
Does US 9,827,242 cover cognitive improvement beyond attention?
The claims provided are restricted to “attention function” and specific attention subdomains, not generic cognition.
-
Can a lurasidone combination regimen infringe US 9,827,242?
The “sole active ingredient” requirement in the claimed composition narrows infringement exposure for products containing any other active ingredient.
-
What dosing limitation matters most in US 9,827,242?
The 20 mg to 160 mg/day band appears in Claim 2 and is tied to tablet administration with lurasidone hydrochloride.
-
Is lurasidone hydrochloride required to practice Claim 1?
No. Claim 1 covers lurasidone or pharmaceutically acceptable acid addition salts; Claim 2 specifically requires hydrochloride.
-
Does US 9,827,242 claim a specific attention test method?
The provided claim text does not identify a test or scoring threshold; it frames attention improvement functionally and by subdomains.
References
- US Patent 9,827,242 (claims excerpt provided in prompt).
More… ↓
⤷ Start Trial
|
